98 related articles for article (PubMed ID: 1493470)
1. The role of intensive chemotherapy in myelodysplastic syndromes.
Fenaux P; Preudhomme C; Hebbar M
Leuk Lymphoma; 1992 Sep; 8(1-2):43-9. PubMed ID: 1493470
[TBL] [Abstract][Full Text] [Related]
2. The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes.
Hirst WJ; Mufti GJ
Leuk Res; 1994 Nov; 18(11):797-804. PubMed ID: 7967705
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Schuler E; Zadrozny N; Blum S; Schroeder T; Strupp C; Hildebrandt B; Kündgen A; Gattermann N; Aul C; Kondakci M; Kobbe G; Haas R; Germing U
Ann Hematol; 2018 Dec; 97(12):2325-2332. PubMed ID: 30078145
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders.
Wattel E; De Botton S; Luc Laï J; Preudhomme C; Lepelley P; Bauters F; Fenaux P
Br J Haematol; 1997 Sep; 98(4):983-91. PubMed ID: 9326199
[TBL] [Abstract][Full Text] [Related]
7. Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases.
Fenaux P; Lai JL; Jouet JP; Pollet JP; Bauters F
Blut; 1988 Nov; 57(5):297-302. PubMed ID: 3196880
[TBL] [Abstract][Full Text] [Related]
8. Therapy of advanced myelodysplastic syndrome with aggressive chemotherapy.
Richard C; Iriondo A; Garijo J; Baro J; Conde E; Recio M; Cuadrado MA; Bello C; Zubizarreta A
Oncology; 1989; 46(1):6-9. PubMed ID: 2644606
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
12. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.
Woods WG; Barnard DR; Alonzo TA; Buckley JD; Kobrinsky N; Arthur DC; Sanders J; Neudorf S; Gold S; Lange BJ
J Clin Oncol; 2002 Jan; 20(2):434-40. PubMed ID: 11786571
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
[TBL] [Abstract][Full Text] [Related]
16. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
Hoyle CF; de Bastos M; Wheatley K; Sherrington PD; Fischer PJ; Rees JK; Gray R; Hayhoe FG
Br J Haematol; 1989 May; 72(1):45-53. PubMed ID: 2736242
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes.
Löffler H; Schmitz N; Gassmann W
Hematol Oncol Clin North Am; 1992 Jun; 6(3):619-31. PubMed ID: 1613010
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
